
Loading summary
A
Hi, everybody. Tune in to this short version of the podcast, which we do every Friday. For the long version, tune in on Wednesdays. Hi everybody. I'm Nicolas Tangen, the CEO of the Norwegian Sovereign Wealth Fund. And today I'm really happy because I'm here with Mala Gaonkar, who I've known for a long time. Actually, Mala founded SergoCap with $1.8 billion and now it's at $6 billion. And before that she spent 23 years as a founding partner of Lone Pine Capital, one of the most successful HED of all times. Great to have you here.
B
Great to be here, Nikolai. Thank you.
A
Tell me about sergiocap Partners. You know your company?
B
Yeah. Sergiocap tries to do what many investment firms try to do. It tries to beat the market over a three to five year cycle with less risk than the market. A risk defined as loss of capital, not volatility. And the way we try to achieve that is by identifying this very small handful of truly great businesses that exist in the world. And we do that through a. Our product is really our process, a very transparent process of looking for very specific factors that really are distillation. As you pointed out earlier of my lessons I've learned the many mistakes and lessons I've learned From investing over 23 years with some of the best people in the business, my former colleagues at Lone Pine. That distillation has led to sergo. There are many different factors that lead to identification of a truly brilliant business. But the way I define a great business is a business with very long duration moats. And duration really is our true differentiation.
A
So moat being that it's difficult to compete with them, it's difficult to compete them out. How many great companies are there in the world?
B
As I said, a small handful. I don't think there are that many. We focus on really four verticals where I think there is a bit of an edge from one very specific factor is every business is a technology business, Right. So if you're an aerospace company or a medtech business, or a financial data business, you are a technology company in your backbone. If you want to deliver at scale and with quality, you have to be a tech business. And I think understanding the tech stack map of businesses is something we spend a lot of time on, especially in non tech businesses. I think that's one. The second is how old technologies can disrupt in very new ways. So if you think about something like we've talked about this, but the auto industry, which employs far more people in the tech industry, but it's being Disrupted right now by technology that was invented in 1976, the lithium ion batteries. So I think that's always interesting to me. Or when we started investing career, we were buying GPUs to make our video games look a little more fun. And then fast forward to now they're actually driving what's probably one of the more tectonic plate shifts in terms of social and demographic and technology shifts of our time, which is AI. How old technologies disrupt in new ways and looking for that in non tech businesses is something we spend a lot of time on as well.
A
What are some of the most counterintuitive benefits of AI that you are seeing in your companies?
B
I think what is happening within medical technologies is not perhaps as well or broadly understood as it should. So to give you a very specific instance, if you look at the imaging space, so MRIs, CT scans and so on, the accuracy and the speed at which these images can be conducted are now improving at a pace of almost 70% versus what we would have even a few years ago. That in an aging demographic globally has been incredibly helpful for not just therapeutic care, but preventive care. And in a way that makes obviously overall care much more cost effective. So I think that is one big area around imaging and really understanding earlier how some of these chronic diseases are evolving. And I think obviously nipping these in the bud earlier has been one big one. The other big area has been around how surgery is conducted. So I think the intersection people talk about AI and robotics in the manufacturing space, what I think people don't realize sometimes is There are about 300 million surgeries conducted globally and they're just beginning to be penetrated by what's happening with robotic surgery, specifically companies like Intuitive Surgical. So I think that is another big category where you're beginning to see real innovation happening, where the combination of haptic feedback mapping software, better technologies around surgical conduct itself are really leading to a lower error, easier training for medical students and a overall better context for how these therapeutic cares can be conducted. As you know, there's a big discussion obviously around how healthcare costs can be contained and I have some hopes that AI applied intelligently can help with this. So yeah, I think broadly this idea of how technology is intersecting with non technology businesses and how you can use data to analyze that and de bias the very human decision making process, something we spend a lot of time on.
A
Now you believe in concentration. You have quite big. When you go for something, you go pretty big, right?
B
Correct.
A
Tell me how you think about concentration.
B
I very intentionally set on these Four verticals that happen to be enterprise data, so tech broadly, financial services and health care services, as well as industrial technologies. Because I felt those were the areas where these themes of emerging technology disruption were most relevant and where you could see market leaders with very durable moats, where incremental returns and the capital you can put to work at those incremental returns had a clearer path, given all the technology trends we're seeing today. So we purely just focus on those four areas. We also think about thematic exposure as well. And the reason for that, I think is very simple. One, I think that allows you to play offense when at some point or the other, due to the passive nature of the market structure. Now, increasingly the odd factor rotation here or there could disrupt a portfolio that allows us to play offense during those periods. And we believe there is actually sufficiently interesting set of investment ideas across each of these four sectors where we're not compromising and we have very different drivers of the long thesis of each of these names.
A
You can also invest in private companies.
B
Yes.
A
Why did you choose to be able to do that?
B
I think some of the. We obviously know about the very large market caps that exist. The very large businesses exist in the private realm, and we know about the fact that there are fewer businesses that are out there in the public markets than have been for a while. So those trends aside, I think another reason to look at the private markets is because they're often the most disruptive. Change always happens at the edges, not at the core. Right. That's my fundamental view. And the edges is really the small company, the private company, the unsung founder who's just emerging, that's really where change at the margin will happen. So making sure that we have our networks and thought processes out there, not just in the U.S. but globally within these four areas that we focus on, these four big industry categories we focus on is something that I think is incumbent upon us. And talking to private companies as part of that process, it's as simple as that.
A
How does shorting compare with long investing? Can the same person do both?
B
It's a great question, because it's really the opposite muscle of the long side, as you know, it's really thinking about. So sometimes you will see clear the shorts that are the broken mirror images of the longs. X is winning, Y is losing. I find those are very rare and few and far between. And that's not enough. Usually. I think in addition to that, you have to have the timing correct as to when exactly those win or loser dynamics will play out. Usually if it plays out through some combination of clear price competitive pressures, clear share competitive pressures leading to those pricing pressures, and then that combined with other factors such as just mis execution by management, you have a pretty good short. The problem, though, is that combination of factors occurring within the time frame you need is a tricky one. And then add to that all of the sort of factor rotations and the passive nature of the markets today, often driven by quant and ETF and other funds. You have other dynamics that are driving trading. You need to think about, do you short? We do short.
A
It's just so, so stressful. I enjoy it because you are wrong for such a long period of time. And when you're right, it's just like in these bursts, you know, and they don't last very long. You may be like super, right for one week and then you're kind of wrong again for two years. You are a role model for many women, and I think when you launched your fund, it was the biggest launch, biggest hedge fund launch of any woman ever, right? That's pretty, pretty amazing. Any reflections around being a woman in the investment world?
B
I would say, look, first of all, I hope that's a record that's broken very quickly, and I'm sure it will be. There's some really amazing, talented women out there. Look, I hope I'm not just a role model for women, but the broader investment community and hopefully over time, the philanthropic community as well. That's a very important part of my work and my ethos, my identity. I would say I really think the investment business, broadly, whether you're an outsider in any way, shape or form, is a great one. It's about as meritocratic a business as I can think of. I could be a green Martian with two horns in my head, but if I produce investment returns, there'll be a line out the door wanting to get my product. I think it's a very meritocratic industry, and I just hope that places like Sergo, places like, you know, the platform you're running here, are just ways for more people to add value in this industry. Because I really think it's a. It's a terrific one for people who are intellectually curious of all stripes and shapes and sizes to come in and be of use to the world at large.
Date: January 23, 2026
Host: Nicolai Tangen (CEO, Norges Bank Investment Management)
Guest: Mala Gaonkar (Founder, SurgoCap Partners; Former Founding Partner, Lone Pine Capital)
In this highlights episode, Nicolai Tangen engages in a candid conversation with Mala Gaonkar, celebrated founder of SurgoCap Partners. Gaonkar reflects on her investment philosophy, the evolution of technology within industries, her approach to risk and concentration, the challenges and thrill of shorting stocks, and her role as a pioneering woman in finance. The discussion is rich with insights on identifying great companies, leveraging private markets, the counterintuitive benefits of AI, and the meritocracy of the investment world.
“The way I define a great business is a business with very long duration moats. And duration really is our true differentiation.”
— Mala Gaonkar [01:21]
"Every business is a technology business… understanding the tech stack map of businesses is something we spend a lot of time on, especially in non tech businesses."
— Mala Gaonkar [01:53]
“…GPUs to make our video games look a little more fun. And then fast forward to now they're actually driving… the more tectonic plate shifts… which is AI.”
— Mala Gaonkar [02:31]
"In the imaging space… the accuracy and the speed at which these images can be conducted are now improving at a pace of almost 70% versus what we would have even a few years ago."
— Mala Gaonkar [03:13]
“…allows you to play offense when at some point or the other, due to the passive nature of the market structure… could disrupt a portfolio that allows us to play offense during those periods.”
— Mala Gaonkar [05:49]
“Change always happens at the edges, not at the core… the private company, the unsung founder who's just emerging, that's really where change at the margin will happen.”
— Mala Gaonkar [06:36]
“I could be a green Martian with two horns in my head, but if I produce investment returns, there'll be a line out the door wanting to get my product.”
— Mala Gaonkar [09:25]
“It's a terrific [industry] for people who are intellectually curious of all stripes and shapes and sizes to come in and be of use to the world at large.”
— Mala Gaonkar [09:51]
On Building SurgoCap’s Process:
“Our product is really our process, a very transparent process of looking for very specific factors…distillation of my lessons I've learned…the many mistakes and lessons…”
— Mala Gaonkar [00:40]
On the Rarity of Great Companies:
“A small handful. I don't think there are that many…”
— Mala Gaonkar [01:44]
On Healthcare AI:
“I think what is happening within medical technologies is not perhaps as well or broadly understood as it should.”
— Mala Gaonkar [03:05]
On Private Vs. Public Opportunity:
“Change always happens at the edges, not at the core… the private company, the unsung founder who's just emerging, that's really where change at the margin will happen.”
— Mala Gaonkar [06:36]
On Investment as Meritocracy:
“I could be a green Martian with two horns in my head, but if I produce investment returns, there'll be a line out the door wanting to get my product.”
— Mala Gaonkar [09:25]
The exchange is analytical yet approachable, mixing technical insights with personal philosophy and humor (notably in Gaonkar’s “green Martian” remark). Both Tangen and Gaonkar refrain from jargon in favor of clear, illustrative examples—making complex ideas accessible and the episode beneficial even for non-specialists interested in leadership, innovation, and finance.